{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:24:31Z","timestamp":1786991071036,"version":"build-2736575974"},"reference-count":69,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000025","name":"NIMH","doi-asserted-by":"publisher","award":["R01MH072567"],"award-info":[{"award-number":["R01MH072567"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"NIMH","doi-asserted-by":"publisher","award":["R01MH122235"],"award-info":[{"award-number":["R01MH122235"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"NIMH","doi-asserted-by":"publisher","award":["R01MH128022"],"award-info":[{"award-number":["R01MH128022"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"NHLBI","doi-asserted-by":"publisher","award":["R01HL126559"],"award-info":[{"award-number":["R01HL126559"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"NINDS","doi-asserted-by":"publisher","award":["F31NS125905"],"award-info":[{"award-number":["F31NS125905"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"NINDS","doi-asserted-by":"publisher","award":["R01NS073899"],"award-info":[{"award-number":["R01NS073899"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"NINDS","doi-asserted-by":"publisher","award":["R01NS124783"],"award-info":[{"award-number":["R01NS124783"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006827","name":"Florida Department of Health","doi-asserted-by":"publisher","award":["8AZ24"],"award-info":[{"award-number":["8AZ24"]}],"id":[{"id":"10.13039\/100006827","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018494","name":"Florida High Tech Corridor Council","doi-asserted-by":"publisher","award":["FHT22-14"],"award-info":[{"award-number":["FHT22-14"]}],"id":[{"id":"10.13039\/100018494","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018494","name":"Florida High Tech Corridor Council","doi-asserted-by":"publisher","award":["FHT22-20"],"award-info":[{"award-number":["FHT22-20"]}],"id":[{"id":"10.13039\/100018494","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002387","name":"NCI","doi-asserted-by":"publisher","award":["L40CA231423"],"award-info":[{"award-number":["L40CA231423"]}],"id":[{"id":"10.13039\/501100002387","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.isci.2023.107461","type":"journal-article","created":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T20:28:29Z","timestamp":1690230509000},"page":"107461","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Anti-amyloid: An antibody to cure Alzheimer\u2019s or an attitude"],"prefix":"10.1016","volume":"26","author":[{"given":"Olivia M.","family":"Osborne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oandy","family":"Naranjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradlee L.","family":"Heckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Dykxhoorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4475-2119","authenticated-orcid":false,"given":"Michal","family":"Toborek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2023.107461_bib1","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/alz.13016","article-title":"2023 Alzheimer's disease facts and figures","volume":"19","author":"Roy","year":"2023","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.isci.2023.107461_bib2","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/alz.12638","article-title":"2022 Alzheimer's disease facts and figures","volume":"18","author":"Harper","year":"2022","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.isci.2023.107461_bib3","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/nrd3505","article-title":"The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics","volume":"10","author":"Karran","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.isci.2023.107461_bib4","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.biopsych.2014.05.006","article-title":"Alzheimer's disease risk genes and mechanisms of disease pathogenesis","volume":"77","author":"Karch","year":"2015","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.isci.2023.107461_bib5","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.neuron.2019.07.010","article-title":"A Large Panel of Isogenic APP and PSEN1 Mutant Human iPSC Neurons Reveals Shared Endosomal Abnormalities Mediated by APP \u03b2-CTFs, Not A\u03b2","volume":"104","author":"Kwart","year":"2019","journal-title":"Neuron"},{"key":"10.1016\/j.isci.2023.107461_bib6","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nature04533","article-title":"A specific amyloid-\u03b2 protein assembly in the brain impairs memory","volume":"440","author":"Lesn\u00e9","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.isci.2023.107461_bib7","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1126\/science.add9993","article-title":"Blots on a field?","volume":"377","author":"Piller","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.isci.2023.107461_bib8","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1093\/brain\/awn016","article-title":"Post-mortem correlates of in\u00a0vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease","volume":"131","author":"Ikonomovic","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.isci.2023.107461_bib9","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.2174\/092986708785909111","article-title":"Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease","volume":"15","author":"Gong","year":"2008","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.isci.2023.107461_bib10","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.neuron.2022.12.012","article-title":"Evolutionarily conserved regulators of tau identify targets for new therapies","volume":"111","author":"Kim","year":"2023","journal-title":"Neuron"},{"key":"10.1016\/j.isci.2023.107461_bib11","doi-asserted-by":"crossref","first-page":"666","DOI":"10.2174\/156720511796717195","article-title":"Tau as a therapeutic target for Alzheimer's disease","volume":"8","author":"Boutajangout","year":"2011","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.isci.2023.107461_bib12","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","article-title":"Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease","volume":"79","author":"Salloway","year":"2022","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.isci.2023.107461_bib13","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","article-title":"Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial","volume":"64","author":"Gilman","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.isci.2023.107461_bib14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/alzrt269","article-title":"Alzheimer\u2019s disease drug-development pipeline: few candidates, frequent failures","volume":"6","author":"Cummings","year":"2014","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.isci.2023.107461_bib15","first-page":"353","article-title":"Why Physicians Should Not Prescribe Aducanumab for Alzheimer Disease","volume":"105","author":"Ebell","year":"2022","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.isci.2023.107461_bib16","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in Early Alzheimer's Disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.isci.2023.107461_bib17","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3390\/healthcare11010032","article-title":"Donanemab for Alzheimer's Disease: A Systematic Review of Clinical Trials","volume":"11","author":"Rashad","year":"2022","journal-title":"Healthcare (Basel)"},{"key":"10.1016\/j.isci.2023.107461_bib18","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1126\/science.adi6515","article-title":"Latest Alzheimer's antibody is 'not a miracle drug'","volume":"380","author":"Travis","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.isci.2023.107461_bib19","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/cpt.2875","article-title":"Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease","volume":"113","author":"Gueorguieva","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.isci.2023.107461_bib20","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ebiom.2016.03.035","article-title":"The Role of Amyloid-\u03b2 Oligomers in Toxicity, Propagation, and Immunotherapy","volume":"6","author":"Sengupta","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.isci.2023.107461_bib21","doi-asserted-by":"crossref","first-page":"14745","DOI":"10.1073\/pnas.0905127106","article-title":"Structure-neurotoxicity relationships of amyloid beta-protein oligomers","volume":"106","author":"Ono","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2023.107461_bib26","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.isci.2023.107461_bib27","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in Early Alzheimer\u2019s Disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.isci.2023.107461_bib28","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13195-020-0580-2","article-title":"Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer's disease","volume":"12","author":"Yoshida","year":"2020","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.isci.2023.107461_bib29","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13195-019-0553-5","article-title":"Characterization of the selective in\u00a0vitro and in\u00a0vivo binding properties of crenezumab to oligomeric A\u03b2","volume":"11","author":"Meilandt","year":"2019","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.isci.2023.107461_bib30","doi-asserted-by":"crossref","first-page":"100","DOI":"10.2967\/jnumed.118.209130","article-title":"Impact of Reference and Target Region Selection on Amyloid PET SUV Ratios in the Phase 1b PRIME Study of Aducanumab","volume":"60","author":"Chiao","year":"2019","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.isci.2023.107461_bib31","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s40035-022-00333-x","article-title":"Enhanced delivery of a low dose of aducanumab via FUS in 5\u00d7FAD mice, an AD model","volume":"11","author":"Kong","year":"2022","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.isci.2023.107461_bib32","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N.\u00a0Engl. J. Med. Overseas. Ed."},{"key":"10.1016\/j.isci.2023.107461_bib33","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1706441","article-title":"Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer\u2019s Disease","volume":"378","author":"Egan","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.isci.2023.107461_bib34","article-title":"Prophylactic evaluation of verubecestat on disease- and symptom-modifying effects in 5XFAD mice","volume":"8","author":"Oblak","year":"2022","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.isci.2023.107461_bib35","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1001\/jamaneurol.2020.4857","article-title":"Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease: A Truncated Randomized Phase 2b\/3 Clinical Trial","volume":"78","author":"Sperling","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.isci.2023.107461_bib36","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1021\/acs.jmedchem.0c01917","article-title":"Discovery of Atabecestat (JNJ-54861911): A Thiazine-Based \u03b2-Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor Advanced to the Phase 2b\/3 EARLY Clinical Trial","volume":"64","author":"Koriyama","year":"2021","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.isci.2023.107461_bib37","doi-asserted-by":"crossref","first-page":"15262","DOI":"10.1021\/acs.jmedchem.1c01300","article-title":"Discovery of Umibecestat (CNP520): A Potent, Selective, and Efficacious \u03b2-Secretase (BACE1) Inhibitor for the Prevention of Alzheimer\u2019s Disease","volume":"64","author":"Machauer","year":"2021","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.isci.2023.107461_bib38","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201809316","article-title":"The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer's disease","volume":"10","author":"Neumann","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.isci.2023.107461_bib39","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/jamaneurol.2019.3988","article-title":"Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials","volume":"77","author":"Wessels","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.isci.2023.107461_bib40","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease","volume":"378","author":"Honig","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.isci.2023.107461_bib41","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00401-015-1489-x","article-title":"Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N-truncated Abeta in sporadic Alzheimer disease cases and mouse models","volume":"130","author":"Bouter","year":"2015","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.isci.2023.107461_bib42","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/s41591-021-01369-8","article-title":"A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease","volume":"27","author":"Salloway","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2023.107461_bib43","doi-asserted-by":"crossref","first-page":"11621","DOI":"10.1523\/JNEUROSCI.1405-14.2014","article-title":"Combined treatment with a BACE inhibitor and anti-A\u03b2 antibody gantenerumab enhances amyloid reduction in APPLondon mice","volume":"34","author":"Jacobsen","year":"2014","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.isci.2023.107461_bib44","first-page":"393","article-title":"Ponezumab in mild-to-moderate Alzheimer's disease: Randomized phase II PET-PIB study","volume":"3","author":"Landen","year":"2017","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.isci.2023.107461_bib45","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/brain\/awv313","article-title":"Passive immunotherapy targeting amyloid-\u03b2 reduces cerebral amyloid angiopathy and improves vascular reactivity","volume":"139","author":"Bales","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.isci.2023.107461_bib46","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3233\/JAD-2012-120805","article-title":"Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study","volume":"33","author":"del Ser","year":"2013","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.isci.2023.107461_bib47","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1016\/S0140-6736(16)31275-2","article-title":"Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial","volume":"388","author":"Gauthier","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2023.107461_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10123191","article-title":"Methylene Blue Delivery Mediated by Focused Ultrasound-Induced Blood-Brain Barrier Disruption Reduces Neural Damage and Amyloid-Beta Plaques by AQP-4\u00a0Upregulation","volume":"10","author":"Choi","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.isci.2023.107461_bib49","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","article-title":"Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization","volume":"61","author":"Orgogozo","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.isci.2023.107461_bib50","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2174\/156720509787602852","article-title":"Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders","volume":"6","author":"Vellas","year":"2009","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.isci.2023.107461_bib51","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13195-018-0441-4","article-title":"Active full-length DNA A\u03b2(42) immunization in 3xTg-AD mice reduces not only amyloid deposition but also tau pathology","volume":"10","author":"Rosenberg","year":"2018","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.isci.2023.107461_bib52","first-page":"262","article-title":"UB-311, a novel UBITh(\u00ae) amyloid \u03b2 peptide vaccine for mild Alzheimer's disease","volume":"3","author":"Wang","year":"2017","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.isci.2023.107461_bib22","doi-asserted-by":"crossref","first-page":"32691","DOI":"10.1073\/pnas.1908658117","article-title":"Clinically approved IVIg delivered to the hippocampus with focused ultrasound promotes neurogenesis in a model of Alzheimer\u2019s disease","volume":"117","author":"Dubey","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2023.107461_bib23","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/s41593-022-01127-0","article-title":"Peripheral apoE4 enhances Alzheimer's pathology and impairs cognition by compromising cerebrovascular function","volume":"25","author":"Liu","year":"2022","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.isci.2023.107461_bib24","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13195-022-01073-w","article-title":"Immuno-digital invasive cleavage assay for analyzing Alzheimer\u2019s amyloid \u00df-bound extracellular vesicles","volume":"14","author":"Yuyama","year":"2022","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.isci.2023.107461_bib25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41746-019-0084-2","article-title":"Digital biomarkers for Alzheimer\u2019s disease: the mobile\/wearable devices opportunity","volume":"2","author":"Kourtis","year":"2019","journal-title":"NPJ Digit. Med."},{"key":"10.1016\/j.isci.2023.107461_bib68","doi-asserted-by":"crossref","first-page":"340","DOI":"10.20517\/evcna.2022.22","article-title":"Brain endothelium-derived extracellular vesicles containing amyloid-beta induce mitochondrial alterations in neural progenitor cells","volume":"3","author":"Osborne","year":"2022","journal-title":"Extracell. Vesicles Circ. Nucl. Acids"},{"key":"10.1016\/j.isci.2023.107461_bib69","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/s41593-023-01334-3","article-title":"Single-nucleus multiregion transcriptomic analysis of brain vasculature in Alzheimer\u2019s disease","volume":"26","author":"Sun","year":"2023","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.isci.2023.107461_bib53","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nrd2111","article-title":"Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases","volume":"6","author":"Mazanetz","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.isci.2023.107461_bib54","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3233\/JAD-2002-4508","article-title":"AbetaPP induces cdk5-dependent tau hyperphosphorylation in transgenic mice Tg2576","volume":"4","author":"Otth","year":"2002","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.isci.2023.107461_bib55","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jamaneurol.2019.4200","article-title":"Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease: A Phase 2 Randomized Clinical Trial","volume":"77","author":"Pagan","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.isci.2023.107461_bib56","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1001\/jamaneurol.2019.3812","article-title":"Reactions to Multiple Ascending Doses of the Microtubule Stabilizer TPI-287 in Patients With Alzheimer Disease, Progressive Supranuclear Palsy, and Corticobasal Syndrome: A Randomized Clinical Trial","volume":"77","author":"Tsai","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.isci.2023.107461_bib57","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2174\/156720507783018208","article-title":"NAP, a neuroprotective drug candidate in clinical trials, stimulates microtubule assembly in the living cell","volume":"4","author":"Gozes","year":"2007","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.isci.2023.107461_bib58","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/s41398-020-00904-4","article-title":"Tauopathy in the young autistic brain: novel biomarker and therapeutic target","volume":"10","author":"Grigg","year":"2020","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.isci.2023.107461_bib59","doi-asserted-by":"crossref","first-page":"780","DOI":"10.14283\/jpad.2022.63","article-title":"Oral Tau Aggregation Inhibitor for Alzheimer's Disease: Design, Progress and Basis for Selection of the 16\u00a0mg\/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate","volume":"9","author":"Wischik","year":"2022","journal-title":"J.\u00a0Prev. Alzheimers Dis."},{"key":"10.1016\/j.isci.2023.107461_bib60","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41392-020-0145-7","article-title":"NLRP3 inflammasome as a novel therapeutic target for Alzheimer\u2019s disease","volume":"5","author":"Zhang","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.isci.2023.107461_bib61","doi-asserted-by":"crossref","first-page":"32145","DOI":"10.1073\/pnas.2009680117","article-title":"The NLRP3 inflammasome inhibitor OLT1177 rescues cognitive impairment in a mouse model of Alzheimer's disease","volume":"117","author":"Lonnemann","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2023.107461_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fdgth.2022.823977","article-title":"Appropriate controls for digital therapeutic clinical trials: A narrative review of control conditions in clinical trials of digital therapeutics (DTx) deploying psychosocial, cognitive, or behavioral content","volume":"4","author":"Lutz","year":"2022","journal-title":"Front. Digit. Health"},{"key":"10.1016\/j.isci.2023.107461_bib63","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1371\/journal.pmed.0020007","article-title":"Educating the brain to avoid dementia: can mental exercise prevent Alzheimer disease?","volume":"2","author":"Gatz","year":"2005","journal-title":"PLoS Med."},{"key":"10.1016\/j.isci.2023.107461_bib64","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.3051","article-title":"Effects of exercise interventions in Alzheimer's disease: A meta-analysis","volume":"13","author":"Roy","year":"2023","journal-title":"Brain Behav."},{"key":"10.1016\/j.isci.2023.107461_bib65","doi-asserted-by":"crossref","first-page":"781","DOI":"10.3233\/JAD-221216","article-title":"Physical Activity for Cognitive Health: A Model for Intervention Design for People Experiencing Cognitive Concerns and Symptoms of Depression or Anxiety","volume":"94","author":"Curran","year":"2023","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.isci.2023.107461_bib66","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41746-021-00506-4","article-title":"Scoping review: the empowerment of Alzheimer\u2019s Disease caregivers with mHealth applications","volume":"4","author":"Kim","year":"2021","journal-title":"NPJ Digit. Med."},{"key":"10.1016\/j.isci.2023.107461_bib67","doi-asserted-by":"crossref","DOI":"10.3389\/fdgth.2023.1086219","article-title":"FDA regulations and prescription digital therapeutics: Evolving with the technologies they regulate","volume":"5","author":"Watson","year":"2023","journal-title":"Front. Digit. Health"}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004223015389?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004223015389?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T17:18:22Z","timestamp":1762881502000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004223015389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":69,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S2589004223015389"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2023.107461","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-amyloid: An antibody to cure Alzheimer\u2019s or an attitude","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2023.107461","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors.","name":"copyright","label":"Copyright"}],"article-number":"107461"}}